Bupropion
- Generic Name
- Bupropion
- Brand Names
- Aplenzin, Auvelity, Budeprion, Contrave, Forfivo, Wellbutrin, Zyban
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18ClNO
- CAS Number
- 34911-55-2
- Unique Ingredient Identifier
- 01ZG3TPX31
- Background
Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the upta...
- Indication
Bupropion is indicated for the treatment of major depressive disorder (MDD), seasonal affective disorder (SAD), and as an aid to smoking cessation.
...
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Major Depressive Disorder (MDD), Obesity, Seasonal Affective Disorder (SAD)
- Associated Therapies
- Smoking, Cessation, Weight Loss
Individualizing Pharmacotherapy for African American Smokers
- Conditions
- Interventions
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 392
- Registration Number
- NCT03897439
- Locations
- 🇺🇸
Swope Health Central, Kansas City, Missouri, United States
A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- Janssen-Cilag International NV
- Registration Number
- NCT03852160
A Prediction Study of Multiple Indexes of the Effect of Different Mechanisms of Antidepressants Treatment on Depression
- Conditions
- Interventions
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2019-09-17
- Lead Sponsor
- Yuqi Cheng
- Target Recruit Count
- 200
- Registration Number
- NCT03623711
- Locations
- 🇨🇳
The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
Assessing Symptomatic Clinical Episodes in Depression
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- Axsome Therapeutics, Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT03595579
- Locations
- 🇺🇸
Clinical Research Site, Bellevue, Washington, United States
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Conditions
- Interventions
- Drug: Tranexamic acid (TXA)Drug: HydrocodoneDrug: labetalolDrug: metforminDrug: nifedipineDrug: oxycodoneDrug: clindamycinDrug: azithromycinDrug: escitalopramDrug: sertralineDrug: CiprofloxacinDrug: ondansetronDrug: DoxycyclineDrug: LevofloxacinDrug: MethylphenidateDrug: CitalopramDrug: SumatriptanDrug: CyclobenzaprineDrug: FurosemideDrug: RosuvastatinDrug: GabapentinDrug: HydrochlorothiazideDrug: HydroxyureaDrug: TrazodoneDrug: TopiramateDrug: ValganciclovirDrug: RemdesivirDrug: VenlafaxineDrug: VerapamilDrug: FluvoxamineDrug: AnakinraDrug: TocilizumabDrug: AmoxicillinDrug: BupropionDrug: BuprenorphineDrug: LevetiracetamDrug: ParoxetineDrug: Duloxetine
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Duke University
- Target Recruit Count
- 1600
- Registration Number
- NCT03511118
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Loma Linda University Health, Loma Linda, California, United States
Bupropion Stereoselective Disposition and CYP2D6-mediated Drug Interactions in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2019-12-23
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 28
- Registration Number
- NCT03420469
- Locations
- 🇺🇸
Indiana Clinical Research Center (ICRC), Indianapolis, Indiana, United States
Smoking Cessation Interventions for People Living With HIV in Nairobi, Kenya
- Conditions
- Interventions
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 300
- Registration Number
- NCT03342027
- Locations
- 🇰🇪
Center for International Health, Education, and Biosecurity (CIHEB), Kilimani, Nairobi, Kenya
A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy
- Conditions
- Interventions
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2019-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 25
- Registration Number
- NCT03301207
- Locations
- 🇪🇸
Hosp. Univ. Fund. Jimenez Diaz, Madrid, Spain
🇵🇱Pratia MCM Krakow, Krakow, Poland
🇵🇱Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu, Wroclaw, Poland
Add-on to Cognitive, Event-Related Potentials (ERP) and Electroencephalogram (EEG) Asymmetry in Affective Disorders
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- New York State Psychiatric Institute
- Registration Number
- NCT03278938
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Metabolism-informed Care for Smoking Cessation
- Conditions
- Interventions
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2017-07-24
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 82
- Registration Number
- NCT03227679
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.